ArticlePloS one2019
Spontaneous ilio-psoas hematomas complicating intensive care unit hospitalizations.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Lumbar Plexus Disorders Presenting as Low Back Pain: A Narrative Review of a Practical Diagnostic Imaging Approach.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Lumbar Artery Pseudoaneurysm Presenting as Psoas Muscle Hematoma Following Vertebral Compression Fracture in an Elderly Patient: A Case Report.Korean journal of neurotrauma · 2026Article
- Gait Training with a Dislocated Hip Spacer: A Case Study and Literature Review.Journal of clinical medicine · 2025Article
- Article
- Transarterial Embolization for Spontaneous Soft-Tissue Hematomas: Predictive Factors for Early Death.Journal of personalized medicine · 2022Article
- Bleeding into the Abdominal and Ilio-Lumbar Muscles-A Rare Complication in the Course of COVID-19: Analysis of Four Cases and a Literature Review.Journal of clinical medicine · 2022Article
- Iliacus Muscle Hematoma an Uncommon Complication in a Rehabilitation Unit: A Case Report Study.Healthcare (Basel, Switzerland) · 2022Article
- Article
- Spontaneous bleeding in COVID-19: A retrospective experience of an Italian COVID-19 hospital.SA journal of radiology · 2022Article
- A Case of Iliopsoas Hematoma Caused by Prophylactic Anticoagulation against COVID-19.Progress in rehabilitation medicine · 2022Article
- Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients.Annals of medicine · 2021Observational
- Psoas Major and Iliopsoas Hematomas without Anticoagulant Therapy as a Complication of Carbon Monoxide Poisoning: A Case Report.The American journal of case reports · 2021Article
- Management of Spontaneous Bleeding in COVID-19 Inpatients: Is Embolization Always Needed?Journal of clinical medicine · 2021Article
- Spontaneous abdominal bleeding associated with SARS-CoV-2 infection: causality or coincidence?Acta bio-medica : Atenei Parmensis · 2021Article
- Catastrophic retroperitoneal hemorrhage in COVID-19 patients under anticoagulant prophylaxis.Urology case reports · 2021Article
- Intramuscular hematoma in rhabdomyolysis patients treated with low-molecular-weight heparin: Report of two cases.World journal of clinical cases · 2021Article
- Plexus-neuropathy due to ilio-psoas hematoma in 4 COVID patients.Medicina clinica (English ed.) · 2021Article
- Plexus-neuropathy due to ilio-psoas hematoma in 4 COVID patients.Medicina clinica · 2021Article
- Coagulative Disorders in Critically Ill COVID-19 Patients with Acute Distress Respiratory Syndrome: A Critical Review.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIlio-psoas hematoma is a potentially lethal condition that can arise during hospital stay. However, neither the incidence nor the prognosis of patients whose stay in intensive care units (ICU) is complicated by a iatrogenic ilio-psoas hematoma is known.
methodsA bicentric retrospective study was conducted to compile the patients who developed an ilio-psoas hematoma while they were hospitalized in ICU between January 2009 and December 2016. Their biometric characteristics, pre-existing conditions, the circumstances in which the hematoma was diagnosed, the treatments they received and their prognosis were recorded.
resultsForty patients were diagnosed with an ilio-psoas hematoma during their ICU stay. The incidence of this complication was 3.8 cases for 1000 admissions, taking into account only patients who stayed more than three days in ICU. The median age of patients was 74 years old and the median time between admission and the diagnosis of ilio-psoas hematoma was 12.6 days. A large proportion of them was obese (42.5%) and/or under dialysis (50%) prior to developing their hematoma. Ninety-five percent of the patients had heparin at prophylactic or therapeutic doses. Only 10% of them were above the therapeutic range of anticoagulation. The ICU mortality rate was of 50% following this complication (versus a general mortality rate of 22% for the patients without IPH over the same period of time). Patients with IPH that were complicated by disseminated intravascular coagulopathy had a significantly higher mortality rate than those with IPH and no disseminated intravascular coagulopathy (OR 6.91, 95% CI [1.28; 58.8], p = 0.04).
conclusionAge, anticoagulation, a high body mass index and dialysis seem to be risk factors of developing an ilio-psoas hematoma in ICU. Iatrogenic ilio-psoas hematomas complicated by disseminated intravascular coagulopathies are more at risk of leading to death. It is noteworthy that activated partial thromboplastin time above the therapeutic range was not a good predictor of developing a hematoma for patients who received unfractioned heparin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.